Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
| Autor: | Melissa Hallow, Bergur V. Stefánsson, Peter Sartipy, Peter Rossing, Valerie A. Cain, Silvio E. Inzucchi, Hiddo J.L. Heerspink, C. David Sjöström |
|---|---|
| Přispěvatelé: | Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET) |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
Endocrinology Diabetes and Metabolism Type 2 diabetes 030204 cardiovascular system & hematology chemistry.chemical_compound 0302 clinical medicine Endocrinology Glucosides Risk Factors Diabetic Nephropathies Dapagliflozin Randomized Controlled Trials as Topic diabetes Brief Report Middle Aged Creatinine Endokrinologi och diabetes Female medicine.symptom Glomerular Filtration Rate medicine.medical_specialty hypertension Urinary system sodium glucose co-transporter-2 Urology Down-Regulation Renal function 030209 endocrinology & metabolism Endocrinology and Diabetes albuminuria 03 medical and health sciences Albumins Diabetes mellitus Internal Medicine medicine Humans Benzhydryl Compounds Aged Retrospective Studies sodium glucose co‐transporter‐2 business.industry dapagliflozin medicine.disease Clinical trial Blood pressure Clinical Trials Phase III as Topic Diabetes Mellitus Type 2 chemistry Albuminuria Brief Reports business Biomarkers Diabetic Angiopathies |
| Zdroj: | Diabetes obesity & metabolism, 21(3), 720-725. Wiley Heerspink, H J L, Sjöström, C D, Inzucchi, S E, Hallow, M K, Cain, V A, Rossing, P, Stefansson, B V & Sartipy, P 2019, ' Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers ', Diabetes, Obesity and Metabolism, vol. 21, no. 3, pp. 720-725 . https://doi.org/10.1111/dom.13579 Diabetes, Obesity & Metabolism Capital Region of Denmark |
| ISSN: | 1462-8902 |
| DOI: | 10.1111/dom.13579 |
| Popis: | The sodium glucose co-transporter-2 inhibitor dapagliflozin has been shown to decrease urinary albumin-to-creatinine ratio (UACR). This effect, however, varies among individual patients. In this study, we assessed the baseline characteristics and concurrent changes in other cardiovascular risk markers that might be associated with UACR response to dapagliflozin. A pooled analysis of 11 phase 3 randomized, controlled clinical trials was performed. UACR change from baseline after 24 weeks treatment with dapagliflozin 10 mg/d in 531 patients with type 2 diabetes and UACR ≥30 mg/g at baseline was determined. UACR response was defined as >30% reduction from baseline at 24 weeks, whereas UACR non-response was defined as ≤30% reduction at 24 weeks. A total of 288 (54%) patients were classified as responders and 243 (46%) as non-responders. At 24 weeks, the UACR-adjusted mean change from baseline was -71.2% and 25.9% in responders and non-responders, respectively. Baseline characteristics were similar between both groups. Changes in HbA1c and body weight were comparable across groups. Responders showed a numerically larger reduction in estimated glomerular filtration rate and systolic blood pressure versus non-responders. UACR reduction to dapagliflozin is an individual characteristic that cannot be predicted by baseline clinical features or changes in metabolic variables. Whether UACR response would improve long-term renal and cardiovascular outcomes remains to be determined. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text